Assertio Holdings, Inc., known by its ticker ASRT, is a prominent pharmaceutical company dedicated to advancing patient care in neurology, orphan, and specialty medicines through developing, marketing, and supplying diverse portfolio of effective and safe products.
Known previously as Depomed, Inc., the company rebranded to Assertio Therapeutics in 2018 before eventually merging with Zyla Life Sciences in 2020 to form Assertio Holdings, Inc. This combined entity, under the helm of CEO Todd Smith, is headquartered in Lake Forest, Illinois. Publicly traded on NASDAQ, the company is committed to providing quality medical solutions to improve patients' lives while creating value for all its stakeholders.
Assertio's portfolio comprises a unique mix of products, including both patented and generic drugs. Its flagship products include CAMBIA®, an acute treatment of migraines; ZIPSOR®, used for relief of mild to moderate acute pain; INDOCIN® for moderate to severe rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis; and SPRIX® Nasal Spray serving as a nonsteroidal anti-inflammatory drug for moderate to moderately severe pain management, among others.
The company has a pipeline of drugs in various stages of clinical trial and development. This underlines its growth strategy focused on internal development, as well as through strategic acquisitions and partnerships. Assertio is dedicated to discovering, developing, and delivering products that provide better therapeutic options to healthcare providers and improve the lives of patients.
Over the years, Assertio Holdings has compiled an impressive record of ensuring safety and efficacy in their products. The company adheres to stringent manufacturing and testing protocols. Rigorous clinical trials, FDA approvals, and continuous post-marketing surveillance are all part of Assertio's commitment to its users' safety.
As at the heart of all endeavors in Assertio is its commitment to corporate social responsibility. The company takes pride in its commitment to communities that it operates in, as well as its dedication towards environmental conservation.
Assertio possesses a strong focus on integrity, transparency, and compliance in its dealings. Its governance practices are designed to ensure strict compliance with laws and regulations, ethical decision-making, and accountability. The company's approach to corporate governance balances the interests of its stockholders, customers, employees, and the wider society.
Despite the challenges faced due to the global health crises, Assertio has made significant strides in recent years. As it continues to navigate the complex pharmaceutical industry landscape, the company's focus remains on leveraging its core capabilities to drive sustainable growth. Assertio is indeed an important player in the pharmaceutical industry, contributing uniquely to medical advancements and patient care.